Breiter Capital Management’s AbbVie ABBV Stock Holding History

Breiter Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$3.66M	Sell	22,587 -51	-0.2%	-$7.41K	1.81%	12
2021 Q4	$3.06M	Buy	22,638 +300	+1%	+$35.4K	1.5%	13
2021 Q3	$2.41M	Buy	22,338 +980	+5%	+$112K	1.38%	15
2021 Q2	$2.41M	Buy	21,358 +847	+4%	+$95.4K	1.29%	18
2021 Q1	$2.22M	Buy	20,511 +168	+0.8%	+$18K	2.28%	14
2020 Q4	$2.18M	Buy	20,343 +1,354	+7%	+$130K	1.51%	14
2020 Q3	$1.66M	Buy	18,989 +321	+2%	+$30.2K	1.36%	19
2020 Q2	$1.83M	Buy	18,668 +12,778	+217%	+$1.13M	1.7%	13
2020 Q1	$449K	Buy	5,890 +3,305	+128%	+$282K	0.53%	61
2019 Q4	$229K	Sell	2,585 -590	-19%	-$49K	0.25%	78
2019 Q3	$240K	Sell	3,175 -360	-10%	-$24.7K	0.32%	74
2019 Q2	$257K	Sell	3,535 -475	-12%	-$37.3K	0.34%	71
2019 Q1	$380K	Buy	4,010 +266	+7%	+$21.8K	0.51%	77
2018 Q4	$345K	Sell	3,744 -123	-3%	-$10.8K	0.7%	54
2018 Q3	$366K	Buy	3,867 +49	+1%	+$4.65K	0.46%	71
2018 Q2	$354K	Sell	3,818 -192	-5%	-$18.8K	0.5%	74
2018 Q1	$380K	Buy	+4,010	New	+$441K	0.51%	76

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Breiter Capital Management's ABBV Position: Q1 2022 in Review

Breiter Capital Management reduced its AbbVie (ABBV) stake by 0.23% in Q1 2022, selling an estimated $7.41K and leaving 22,587 shares worth $3.66M. The position accounts for 1.81% of the portfolio, ranked #12.

Breiter Capital Management first reported a position in ABBV in Q1 2018 and has held it in 17 quarters since. 3,052 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

Breiter Capital Management held 22,587 shares of AbbVie worth $3.66M as of Q1 2022.
Breiter Capital Management sold 51 AbbVie shares in Q1 2022, an estimated $7.41K.
AbbVie made up 1.81% of Breiter Capital Management's portfolio in Q1 2022, its #12 holding.
Breiter Capital Management first reported a position in AbbVie in Q1 2018 and has held it in 17 quarters since.
3,052 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on Breiter Capital Management's 13F filing for Q1 2022, filed 11 May 2022.